EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development

Andrew D J Pearson iD, Teresa de Rojas, Dominik Karres, Gregory Reaman, Nicole Scobie, Elizabeth Fox, Giovanni Lesa, Franca Ligas, Koen Norga, Karsten Nysom, Alberto Pappo, Brenda Weigel und 2 weitere

JNCI: Journal of the National Cancer Institute · 2024

DOI: 10.1093/jnci/djad239 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Andrew D J Pearson und 13 weiteren Autor:innen. Beteiligte Einrichtung: ACCELERATE, Brussels, Belgium, Europe. Hauptthemen laut MEDLINE: Drug Development, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Andrew McDonough B+ Foundation, Alex's Lemonade Stand Foundation, Fifth Paediatric Strategy Forum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In a landscape of an increasing number of products and histology and age agnostic trials for rare patient cancer, prioritization of products is required. Paediatric Strategy Forums, organized by ACCELERATE and the European Medicines Agency with participation of the US Food and Drug Administration, are multi-stakeholder meetings that share information to best inform pediatric drug development strategies and subsequent clinical trial decisions. Academia, industry, regulators, and patient advocates are equal members, with patient advocates highlighting unmet needs of children and adolescents with cancer. The 11 Paediatric Strategy Forums since 2017 have made specific and general conclusions to accelerate drug development. Conclusions on product prioritization meetings, as well as global master protocols, have been outputs of these meetings. Forums have provided information for regulatory discussions and decisions by industry to facilitate development of high-priority products; for example, 62% of high-priority assets (agreed at a Forum) in contrast to 5% of those assets not considered high priority have been the subject of a Paediatric Investigational Plan or Written Request. Where there are multiple products of the same class, Forums have recommended a focused and sequential approach. Class prioritization resulted in an increase in waivers for non-prioritized B-cell products (44% to 75%) and a decrease in monotherapy trials, proposed in Paediatric Investigation Plans (PIP) submissions of checkpoint inhibitors from 53% to 19%. Strategy Forums could play a role in defining unmet medical needs. Multi-stakeholder forums, such as the Paediatric Strategy Forum, serve as a model to improve collaboration in the oncology drug development paradigm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentNeoplasmsAdolescentChildHumansMedical OncologyB-Lymphocytes

Autor:innen und Institutionen

  • ACCELERATE, Brussels, Belgium, Europe.
  • Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Amsterdam, The Netherlands.
  • US Food and Drug Administration (FDA), Silver Spring, MD, USA.
  • Zoe4Life, Vaud, Sullens, Switzerland.
  • St Jude Children's Research Hospital, Memphis, TN, USA.
  • Antwerp University Hospital, Antwerp, Belgium.

ORCID-Profile: Andrew D J Pearson

Förderung

  • Andrew McDonough B+ Foundation
  • Alex's Lemonade Stand Foundation
  • Fifth Paediatric Strategy Forum
  • Alan B. Slifka Foundation
  • Children's Cancer Cause Dana Farber Cancer Institute
  • Boston Children's Hospital, National Brain Tumor Society
  • Pediatric Brain Tumor Foundation
  • Rally Foundation for Childhood Cancer Research

Zitieren

APA

Pearson, A. D. J., de Rojas, T., Karres, D., Reaman, G., Scobie, N., Fox, E., Lesa, G., Ligas, F., Norga, K., Nysom, K., Pappo, A., Weigel, B., Weiner, S. L., & Vassal, G. (2024). Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djad239

Vancouver

Pearson ADJ, de Rojas T, Karres D, Reaman G, Scobie N, Fox E, et al. Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djad239

BibTeX
@article{Pearson2024,
  author = {Pearson, Andrew D J and de Rojas, Teresa and Karres, Dominik and Reaman, Gregory and Scobie, Nicole and Fox, Elizabeth and Lesa, Giovanni and Ligas, Franca and Norga, Koen and Nysom, Karsten and Pappo, Alberto and Weigel, Brenda and Weiner, Susan L and Vassal, Gilles},
  title = {Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  doi = {10.1093/jnci/djad239}
}
Kostenlos starten →